

Cover Story
COVID-19 & CancerFreeGuest Editorial
By Karen E. Knudsen and Roy A. Jensen
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.As COVID-19 has now officially been declared a source of the pandemic, with increasing incidence across the nation, it is without question that the needs of patients with particular vulnerabilities should garner particular attention.
COVID-19 & CancerFree
By Alexandria Carolan and Matthew Bin Han Ong
Clinical Roundup
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Oncology has a semantics problem: How do we define “early stage”?
















